Cannabix Technologies Announces Delivery of Marijuana Breath Test (MBT) to Virginia based Industrial Manufacturing Client
MWN-AI** Summary
Cannabix Technologies Inc. (CSE: BLO) has announced the successful delivery of its Marijuana Breath Test (MBT) products to a prominent industrial manufacturing client in Virginia, marking a significant milestone for the company. This delivery, completed via an authorized reseller, underscores the increasing acceptance and adoption of Cannabix’s innovative, non-invasive breath-testing solutions across varied sectors, particularly those with stringent safety protocols.
The industrial manufacturing sector has been facing heightened concerns over cannabis use due to a rise in THC-related safety incidents and the inadequacies of traditional drug testing methods. These issues are compounded by labor shortages that make it challenging for employers to manage employees based solely on outdated drug tests, which often detect cannabis exposure from days or weeks prior rather than recent use.
Cannabix's MBT is engineered to detect delta-9 THC in breath within a four-hour window after consumption, providing a timely solution to assess current impairment related to cannabis use. This modern approach is critical in environments where reaction time and situational awareness are paramount, as industries like manufacturing operate heavy machinery and require rigorous safety protocols.
Rav Mlait, CEO of Cannabix, emphasized that the company’s MBT system aligns with modern industrial needs. The delivery to the Virginia client exemplifies the demand for scientifically valid testing methods that focus specifically on recent cannabis usage. As Cannabix positions its product within safety-sensitive industries, it aims to redefine standards for drug testing, ensuring occupational safety while keeping pace with the changing legal landscape surrounding cannabis.
The strategic partnership with Omega Laboratories enhances Cannabix’s ability to deliver accurate, compliant, and prompt testing solutions, aiming to set a new benchmark in workplace safety in response to increasing cannabis prevalence in the workforce.
MWN-AI** Analysis
Cannabix Technologies Inc. (CSE: BLO) has taken a significant step forward in the burgeoning field of workplace safety with the successful delivery of its Marijuana Breath Test (MBT) to a major industrial client in Virginia. This marks a pivotal moment for the company, as industries grapple with the ramifications of cannabis legalization and its impact on workplace safety.
The industrial manufacturing sector, characterized by its safety-sensitive operations, is under increasing pressure to adopt reliable testing methods that more accurately assess recent cannabis use. Legacy drug testing methods are often outdated, failing to account for the short detection windows necessary to evaluate workplace readiness. The MBT’s ability to detect delta-9 THC levels shortly after use places it in a prime position to serve evolving industry needs.
Investors should be aware of several strategic aspects of Cannabix's market position. With mounting concerns about workplace injuries linked to cannabis use and significant compliance pressures from insurance firms and regulatory bodies, the potential for widespread adoption of the MBT is compelling. The company is not only addressing a market gap but also aligning itself with a growing industry trend toward accuracy and fairness in employee testing.
Moreover, Cannabix's strategic partnership with Omega Laboratories enhances its credibility and operational capabilities, further solidifying its position in the market for cannabis testing technologies. As the company works to scale its operations and attract additional business, investors might consider Cannabix a strong contender in a niche market with substantial growth potential.
In summary, Cannabix Technologies represents a unique investment opportunity, particularly as workplace safety concerns continue to grow in the cannabis context. Given its innovative approach and the strategic need for accurate testing solutions, Cannabix is positioning itself as a leader in a transformative market landscape. Investors should monitor Cannabix closely for developments in client adoption and technological advances, as these will be critical in driving future growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
VANCOUVER, British Columbia, April 01, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce the commercial delivery of its Marijuana Breath Test (“MBT”) products to a leading industrial manufacturing company with operations in the state of Virginia. The delivery was completed through an authorized reseller. The announcement highlights diverse industries that are adopting the Company’s non-invasive breath-based testing products to support workplace safety programs.
The client, which operates large-scale custom machinery fabrication, sought a scientifically grounded method to assess recent cannabis use among its workforce amid growing concerns about THC-related safety incidents and the limitations of traditional drug testing.
Manufacturing Sector Faces Rising Cannabis-Related Safety Pressures
Industrial manufacturing environments—particularly those involving production lines, machining, robotics, welding, electrical systems, and material-handling equipment—are among the most safety-sensitive workplaces in the U.S. Employers across the sector report increasing challenges related to cannabis use, including:
- Higher rates of workplace injuries associated with safety-relevant reaction time and reduced situational awareness
- Labor shortages, making it difficult to suspend or replace employees based solely on legacy drug tests
- Outdated testing methods (urine, saliva) that detect cannabis exposure from days or weeks prior
- Legal and policy conflicts resulting from state-level legalization of recreational and medical marijuana
- Insurance and compliance pressures requiring clearer documentation of safety-relevant testing
Manufacturing employers are especially impacted because they operate heavy equipment, must maintain strict safety programs, and cannot rely on drug tests that fail to distinguish recent cannabis use from historical use.
MBT: A Modern, Non-invasive Tool for Detecting Recent Cannabis Use
The Cannabix MBT system is designed to detect delta-9 THC—the primary psychoactive compound in cannabis—in breath within four hours of use, at levels above 5 pg/L. This short detection window aligns closely with the period most correlated with recent-use effects, offering a valuable alternative to legacy drug tests that identify past consumption. The MBT includes Cannabix’s proprietary Breath Collection Unit and Breath Cartridge technologies (see Figure 1) to collect and preserve breath samples for laboratory analysis using gold-standard liquid chromatography-mass spectrometry (LC-MS) methods. This window aligns closely with recent-use timeframes, offering an actionable alternative to legacy tests that detect past exposure.
Figure 1. Cannabix Technologies Breath Collection Unit (BCU)
“As industrial workplaces evolve and cannabis use becomes increasingly commonplace, manufacturers require tools that deliver fairness and scientific relevance,” said Rav Mlait, CEO of Cannabix Technologies Inc. “Our early delivery of the MBT system to a major manufacturing client in Virginia demonstrates the growing interest for accurate, non-invasive testing that focuses specifically on recent cannabis use. This news highlights the MBT’s readiness for deployment across high-risk industries that cannot compromise on safety.”
Strategic and Investor-Focused Outlook
This delivery marks another step in Cannabix’s commercialization strategy, reinforcing the Company’s competitive position within safety-sensitive industries. Industrial manufacturing represents a substantial near-term market opportunity due to:
- The sector’s dependence on skilled labor operating high-risk equipment
- Increased THC-related incidents reported across U.S. manufacturing worksites
- Heightened insurance requirements and safety audits
- A shift toward recent-use testing tools rather than legacy exposure-based methods
Cannabix is working to position the MBT as a new standard for detecting recent cannabis use across multiple safety-critical industries. The Company believes the MBT platform is well positioned to become a new standard for detecting recent cannabis use among employers with safety-critical operations. Cannabix maintains a strategic partnership with Omega Laboratories, Inc., a global leader in forensic drug testing for over 25 years, operating a fully accredited laboratory with extensive experience in novel drug-detection technologies.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. The Marijuana Breath Test (MBT) targets delta-9 THC (the primary psychoactive ingredient in cannabis) in breath and focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring. Visit www.cannabixtechnologies.com
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). All statements in this release that are not purely historical in nature should be considered forward-looking statements, including, without limitation, statements regarding: the Company’s plans for the commercial rollout of the MBT system; anticipated customer adoption and market demand; expectations related to manufacturing scale-up, recurring revenue streams, and operational processes; potential technological developments or enhancements; future partnerships or commercial agreements; regulatory approvals; and the Company’s ability to complete future financings or achieve other business milestones. Forward-looking statements are often identified by terminology such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “project,” “proposed,” “target,” “will,” and similar expressions, or statements that events or conditions “may” or “will” occur. These statements are based on the beliefs, assumptions, and expectations of management in light of currently available information. Forward-looking statements involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company’s control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: adverse market conditions; the Company’s ability to successfully manufacture, deploy, and commercialize the MBT system or any future products; risks associated with regulatory approvals and evolving legal frameworks for cannabis testing; reliance on third-party laboratory and manufacturing partners; the protection and enforceability of intellectual property rights; technological uncertainties; competition; potential delays in product development or customer adoption; risks related to future financings; and the possibility that strategic partnerships may not advance as expected or may not be completed at all. Readers are cautioned that undue reliance should not be placed on forward-looking statements. Actual results and future events may differ materially from those expressed or implied by such statements. Forward-looking statements in this release are provided as of the date hereof, and the Company undertakes no obligation to update or revise any forward-looking statements except as required under applicable securities laws.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/840bbe00-88ad-47fb-8fb5-0e2945da67d2
FAQ**
How does Cannabix Technologies Inc (CSE: BLO) plan to scale its Marijuana Breath Test (MBT) product to meet increasing demand in high-risk industries, especially concerning THC-related safety incidents?
What are the potential regulatory challenges Cannabix Technologies Inc BLOZF may face in the commercialization of its breath testing technology, especially as laws around cannabis evolve?
Can Cannabix Technologies Inc (OTCID: BLOZF) provide insights into the effectiveness and accuracy of its MBT system compared to traditional drug testing methods currently used in industrial settings?
How does Cannabix Technologies Inc BLOZF aim to address market competition and maintain its unique position as a provider of recent-use cannabis testing solutions in the manufacturing sector?
**MWN-AI FAQ is based on asking OpenAI questions about Cannabix Technologies Inc (OTC: BLOZF).
NASDAQ: BLOZF
BLOZF Trading
-0.7% G/L:
$0.4537 Last:
43,884 Volume:
$0.42435 Open:
